This site is intended for health professionals only

Published on 22 April 2010

Share this story:
Twitter
LinkedIn

H. Lundbeck A/S held its Annual General Meeting on 20 April 2010

teaser

At the general meeting the report by the Supervisory Board and the Annual Report were approved, and the Supervisory Board and Executive Management were discharged from liability.

The general meeting approved the dividend of DKK 602 million or DKK 3.07 per share of DKK 5 nominal value proposed by the Supervisory Board.

Per Wold-Olsen, Thorleif Krarup, Peter Kurstein, Mats Pettersson, Jes stergaard and Egil Bodd were all re-elected to the Supervisory Board. Immediately after the general meeting, the Supervisory Board elected Per Wold-Olsen Chairman and Thorleif Krarup Deputy Chairman of the Supervisory Board.

After having elected its Chairman and Deputy Chairman, the Supervisory Board appointed members for the Audit Committee, the Remuneration Committee and the recently established Scientific Committee.

Peter kurstein, Egil Bodd and Thorleif Krarup were re-elected as members of the Audit Committee. Per Wold-Olsen, Jes Ostergaard and Mats Pettersson were re-elected as members of the Remuneration Committee. Egil Bodd, Jes Ostergaard and Mats Pettersson were re-elected as members of the Scientific Committee.

The Supervisory Board of H. Lundbeck A/S willz hereafter comprise: Per Wold-Olsen, Thorleif Krarup, Peter Kurstein, Mats Pettersson, Jes Ostergaard, Egil Bodd, Mona Elster (employee representative), Jorn Moller Mayntzhusen (employee representative), Kim Rosenville Christensen (employee representative)

Deloitte Statsautoriseret Revisionsaktieselskab was re-appointed as the company’s auditor.

The proposed amendments to the Articles of Association by the Supervisory Board based on the new Danish Companies Act and as a result of a general update were adopted.

The Supervisory Board was authorised until the next annual general meeting to let the company acquire treasury shares with a total nominal value of up to 10% of the share capital at a purchase price of the shares in question, that may not deviate.

The content of this release will have no influence on the Lundbeck Group’s financial result for 2010.



Most read



Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn